An Act relative to prescription drug price transparency: The commission, in consultation with the center, shall create annually a list of 10 drugs on which the commonwealth’s MassHealth program spends significant health care dollars and for which the wholesale acquisition cost has increased by 50 percent or more over the past five years or by 15 percent or more during the previous calendar year, or both. The list shall include at least one generic and one brand name drug and shall indicate each of the drugs on the list that the commission considers specialty tier drugs. Requires drug manufacturers to provide information to justify increases in costs.